The landscape of flu vaccination has undergone a dramatic transformation in the past year. On August 5, 2026, the Department of Health and Human Services made a controversial decision to cancel 22 mRNA vaccine projects, worth approximately $500 million, and halt investments in this innovative technology. Health Secretary Robert F. Kennedy Jr., known for his skepticism toward vaccines, asserted that mRNA vaccines were ineffective against upper respiratory infections like Covid and flu. This claim was contradicted by Moderna’s published Phase 3 trial results, but it sparked a year of uncertainty and debate.
Fast forward to August 5, 2026, exactly one year later, the Food and Drug Administration (FDA) approved mFLUSIVA the first mRNA influenza vaccine licensed in the United States. This approval, coinciding with the anniversary of the initial decision, was not planned but resulted from the FDA’s self-imposed deadline set in February of this year. Despite the lack of extensive media coverage, this approval represents a significant advancement in flu prevention technology.
The limitations of traditional flu vaccines
Traditional flu vaccines have relied on a method involving fertilized chicken eggs since the 1940s. This process is time-consuming and labor-intensive, taking about nine to 12 days of incubation per batch. The World Health Organization spends months creating the necessary reagents for manufacturers to calibrate doses, resulting in a total production time of around six months. This delay means that the flu strains in the vaccine by November were selected back in February, leaving room for the virus to mutate and become less effective.
The use of chicken eggs also presents another challenge. Growing the flu virus in eggs forces it to adapt to egg cells, altering the surface protein that the vaccine is designed to target. Between the 2011 and 2026 flu seasons, these egg-adaptive mutations caused more mismatches than the virus’s natural drift. This mismatch reduces the vaccine’s effectiveness, which varies between 20% and 60% depending on how well the February strain matches the November virus.
The advantages of mRNA technology
The mRNA vaccine, mFLUSIVA bypasses the need for chicken eggs. Instead, it carries instructions in the form of genetic code that tells your cells to build the flu’s surface protein. Your immune system then learns to attack this protein. This method allows for a quicker production process, with Moderna claiming it can go from strain selection to finished vaccine in two to three months instead of six. This reduction in time means that strain picks can be made later, closer to the season they cover, and a novel flu virus surfacing in September could still be blocked by a reformulated vaccine in the same season.
The approval of mFLUSIVA is not just a victory for flu prevention but also a testament to the potential of mRNA technology. This platform has shown promise in various applications, from cancer treatments to personalized gene-editing therapies. The unanimous approval by nine experts appointed under the same secretary who initially opposed mRNA technology highlights the strength of the evidence supporting this technology.
Challenges and future prospects
Despite the promising results, there are still challenges to overcome. The mFLUSIVA vaccine reported higher rates of injection-site pain compared to standard-dose flu shots, which could deter some individuals from getting vaccinated. Additionally, the lack of a clinical recommendation from the CDC’s vaccine advisory committee, which has been frozen by a federal court since March, means that insurers are not required to cover mFLUSIVA at no cost. The $500 million in canceled contracts has not been restored, leaving the future of mRNA vaccine development in the United States uncertain.
Looking ahead, the approval of mFLUSIVA could pave the way for more advanced flu vaccines, including a universal flu vaccine that covers all strains for years. The mRNA platform’s flexibility and speed make it an ideal candidate for such innovations. However, it is crucial to address the current challenges and ensure widespread access to these advanced vaccines to fully realize their potential.
